Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2010

View Archived Issues

Preclinical and first-in-human data reported on GSK-1292263 for type 2 diabetes

PCDH10 gene methylation status is biomarker for risk of cervical cancer in hrHPV infection

A-918446 and A-801195 show preclinical promise for treatment of AD

Biomarkers of oxidative stress correlate with HPV clearance

Taspoglutide is superior to comparators in improving glycemic control in phase III diabetes trials

Mesoblast to manufacture and supply adult stem cell products in Australia

Lilly acquires Alnara Pharmaceuticals

Prolor Biotech's hGH-CTP enters phase II trial in growth hormone deficiency

Access Pharma and BioScrip sign MuGard distribution agreement

Novartis' Rasilez approved in China for high blood pressure

Pharmasset claims new NS5B inhibitors

Merck & Co. discloses new gamma-secretase modulators

Health Canada grants priority review for Prochymal NDS

New PLK-1 inhibitors discovered by Rigel

Gilead Sciences reports highlights of second quarter 2010

Sirtris Pharmaceuticals describes new sirtuin modulators

Curis identifies novel CDK inhibitors

Abbott updates developments of second quarter 2010

Ampio begins phase II trial of oral Optina in diabetic macular edema

Fera Pharmaceuticals acquires itraconazole topical suspension

GSK suspends enrollment in TIDE trial at FDA's request

Tamir agents are efficacious against SARS virus in vitro

Onyx begins phase III carfilzomib combination trial in relapsed multiple myeloma

FDA recommends further naproxcinod trials in complete response letter to NicOx

Preliminary phase IIb data disclosed on S/GSK-1349572 for HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...